Unlocking NSCLC Treatments: A Deep Dive into CodeBreaK 200 Lung 14 Mins Read1 Sotorasib, as demonstrated by the CodeBreaK 200 study, is a promising treatment for patients with KRAS G12C-mutated advanced NSCLC, with…
Biomarker Subgroup Analyses Pretreated KRAS G12C-Mutated NSCLC Patients Benefit from Sotorasib Lung 3 Mins Read4 Ferdinandos Skoulidis, MD, PhD, from the MD Anderson Cancer Center, presented the results of biomarker subgroup analyses from the phase…
